LLY vs PRAX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Praxis Precision Medicines continues to advance its promising CNS pipeline, notably with the presumed NDA submission for PRAX-118 by end of 2025, a significant de-risking event reflected in its increased market cap to $8.97B. The company targets large, underserved markets (Essential Tremor, Epilepsies) with strong IP and novel mechanisms. While financial health remains a key watchpoint as a pre-co...